Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Encorafenib Monotherapy in Chinese Patients with BRAF V600E-mutated Advanced Solid Tumors
NCT05003622Phase 1Completed
- Sponsor
- Pierre Fabre Laboratories
- Start
- Sep 2021
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of encorafenib in melanoma and non-small cell lung cancer (NSCLC), sponsored by Pierre Fabre Laboratories. Primary endpoint: Dose Limiting Toxicities. Started Sep 2021; status: completed.
02
Drugs
encorafenib
03
Conditions
melanomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05003622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05003622.